[ RECIPIENT ENTITY RECORD ]

ImmunoGen

VERIFIED NODE ID: 001380 · immunogen
R TARGET NODE — CAPITAL RECIPIENT
ImmunoGen
Company United States
Recipient Type
Company
Primary Jurisdiction
United States
Registration Status
ACTIVE
Entity Intelligence [ R ]
Legal Name ImmunoGen
Entity Type Company
Jurisdiction United States
Recipient Intelligence Summary

ImmunoGen is a biotechnology company focused on developing antibody-drug conjugates for the treatment of cancer. Based in Massachusetts, the firm’s innovative technology targets tumors while sparing healthy tissue. It is a primary recipient of institutional healthcare capital through strategic pharmaceutical acquisitions.

Capital Influx Log (Transactions)
Date Type Amount
19 May 2026 EQUITY $10.1B